Johnson & Johnson MedTech Unveils New VARIPULSE Data

Johnson & Johnson MedTech, a cardiac arrhythmia treatment global leader, said that new clinical and real-world results of its VARIPULSE Platform in pulsed field ablation (PFA) of atrial fibrillation (AF) would be revealed at the Asia Pacific Heart Rhythm Society (APHRS) and Japanese Heart Rhythm Society (JHRS) annual meeting in November 12-15 in Yokohama.

It is now approved in the U.S., Europe, Asia Pacific, Canada, and Latin America with the integrated-by-design VARIPULSE Platform, comprising of the VARIPULSE Catheter, TRUPULSE Generator and CARTO 3 Mapping System.

Also Read: How Emerging Biotech Startups Reshaping the Bioprocessing Future

There are more than 25,000 PFA surgeries already made around the world, which speaks to the increased clinical acceptance and stability of the platform. Johnson & Johnson MedTech will present new data to support the safety, efficiency and performance of the VARIPULSE Platform in the form of a series of orals and poster presentations, as well as in workshops and scientific symposia at APHRS and JHRS 2025.

“Our presentations this year reflect our commitment to advancing innovation in atrial fibrillation treatment,” said Jing Li, Vice President, Electrophysiology & Neurovascular, Asia Pacific MedTech. “The VARIPULSE Platform, combined with the CARTO 3 Mapping System, represents a major leap forward in precision and procedural efficiency.”

With ongoing trials such as QUEST AF, VARIPURE (SECURE), admIRE, and REAL AF, Johnson & Johnson MedTech continues to expand real-world insights and strengthen its leadership in atrial fibrillation care, driving the next era of patient-centered cardiovascular innovation.